Revenue
2009
2010
2011
2012
2017
2018
2019
2020
2021
2022
2023
2024
2025
Madrigal Pharmaceuticals, Inc. (MDGL)
Price$541.08Cached quote
Net income
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $958.4M | $180.1M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | — | — | — | — | $147,000 | $7.6M | $14.8M | $144.2M |
| Gross profit | $902.3M | $173.9M | $0 | $0 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Gross margin | 94.14% | 96.54% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Research & development | $388.5M | $236.7M | $272.4M | $245.4M | $205.2M | $184.8M | $72.3M | $25.4M | $24.4M | $15.9M | $2.4M | $68.2M | $71.9M | $49.4M | $41.5M | $40.3M | $51.1M |
| Operating expenses | $1.26B | $678.0M | $380.5M | $293.6M | $242.5M | $206.7M | $95.0M | $40.7M | $32.1M | $25.2M | $3.2M | $84.0M | $87.6M | $61.1M | $53.0M | $51.7M | $64.9M |
| Operating income | −$300.1M | −$497.9M | −$380.5M | −$293.6M | −$242.5M | −$206.7M | −$95.0M | −$40.7M | −$32.1M | −$25.2M | −$3.2M | −$84.0M | −$87.6M | −$60.9M | −$45.4M | −$36.9M | $79.3M |
| Operating margin | −31.31% | −276.39% | — | — | — | — | — | — | — | — | — | — | — | −41,456.46% | −599.05% | −249.26% | 54.98% |
| EBITDA | −$298.6M | −$496.8M | −$380.0M | −$293.1M | −$242.1M | −$206.2M | −$94.9M | −$40.6M | −$32.0M | −$25.2M | −$2.6M | −$83.3M | −$87.0M | −$60.2M | −$44.0M | −$35.0M | $81.8M |
| EBITDA margin | −31.16% | −275.78% | — | — | — | — | — | — | — | — | — | — | — | −40,954.42% | −579.75% | −236.20% | 56.69% |
| Net income | −$288.3M | −$465.9M | −$373.6M | −$295.4M | −$241.8M | −$202.2M | −$83.9M | −$32.8M | −$31.2M | −$26.4M | — | — | — | — | — | — | — |
| Net profit margin | −30.08% | −258.64% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Basic EPSper basic share | -$12.85 | -$21.90 | -$19.99 | -$17.23 | -$14.63 | -$13.09 | -$5.45 | -$2.22 | -$2.54 | -$5.07 | -$40.03 | -$0.87 | -$1.27 | -$1.06 | -$1.00 | -$0.93 | $2.33 |
| Diluted EPSper diluted share | -$12.85 | -$21.90 | -$19.99 | -$17.23 | -$14.63 | -$13.09 | -$5.45 | -$2.22 | -$2.54 | -$5.07 | -$40.03 | -$0.87 | -$1.27 | -$1.06 | -$1.00 | -$0.93 | $2.32 |
Owners
Reported shareholders
9.28%of listed shares
BAKER BROS. ADVISORS LP2.14M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
BAKER BROS. ADVISORS LP | 9.28%2.14M shares |
RTW INVESTMENTS, LP | 8.63%1.99M shares |
Jupiter Topco LLC | 8.38%1.94M shares |
Avoro Capital Advisors LLC | 7.94%1.83M shares |
PAULSON & CO. INC. | 5.80%1.34M shares |
BlackRock, Inc. | 5.20%1.2M shares |
Taub Rebecca | ≈4.80%1.11M shares |
VANGUARD CAPITAL MANAGEMENT LLC | 3.62%835.67K shares |
WELLINGTON MANAGEMENT GROUP LLP | 3.58%825.71K shares |
VANGUARD PORTFOLIO MANAGEMENT LLC | 3.38%781.73K shares |
STATE STREET CORP | 2.28%527.06K shares |
CITADEL ADVISORS LLC | 2.20%507.23K shares |
UBS Group AG | 1.74%401.71K shares |
GEODE CAPITAL MANAGEMENT, LLC | 1.62%374.88K shares |
FMR LLC | 1.54%356.2K shares |
WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC | 1.40%324.12K shares |
Invesco Ltd. | 1.31%301.44K shares |
ARMISTICE CAPITAL, LLC | 1.25%288K shares |
LORD, ABBETT & CO. LLC | 1.22%281.5K shares |
Assenagon Asset Management S.A. | 1.08%248.43K shares |
Percentages use 23.09M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 1, 2026Form 4 · 10b5-1 | Soergel DavidChief Medical Officer | SellCommon Stock | 1.0K | $495.74 | $516.6K | 10.0K |
| May 22, 2026Form 4 · 10b5-1 | Levy Richard SDirector | SellCommon Stock | 80 | $519.98 | $41.6K | 22.0K |
| May 22, 2026Form 4 · 10b5-1 | Levy Richard SDirector | SellCommon Stock | 782 | $518.76 | $405.7K | 22.1K |
| May 22, 2026Form 4 · 10b5-1 | Levy Richard SDirector | SellCommon Stock | 1.5K | $517.59 | $774.8K | 22.9K |
| May 22, 2026Form 4 · 10b5-1 | Levy Richard SDirector | SellCommon Stock | 723 | $516.87 | $373.7K | 24.4K |